China develops effective breast cancer treatment

Shanghai medical experts have developed an innovative neoadjuvant treatment approach for triple-negative breast cancer, one of the most aggressive forms of the disease, significantly increasing the rate of tumor disappearance before surgery from 44.7 percent to 56.8 percent.

The research, led by Fudan University Shanghai Cancer Center, combines traditional chemotherapy with Camrelizumab, a novel Chinese-developed immunotherapy drug. The treatment helps shrink tumors and extends patient survival, researchers said Tuesday.

The phase III clinical trial involved 441 patients from 40 hospitals across China and was the first one on an original breast cancer medicine based on data from the Chinese population to be published in the prestigious Journal of the American Medical Association.